Russell A Judge - JoVE Visualize

Showing results (31-40 of 37) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 37 results.

Communications Medicine|October 25, 2023

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.

Nature Cancer|March 8, 2022

An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapySarah Chan, Nicole Belmar, Sun Ho, et al.

Molecular Cancer Therapeutics|March 31, 2021

Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.

ACS Medicinal Chemistry Letters|October 16, 2020

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.

Journal of Medicinal Chemistry|November 3, 2018

Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug DesignAdrian D Hobson, Russell A Judge, Ana L Aguirre, et al.

ACS Medicinal Chemistry Letters|October 15, 2014

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.

Science Advances|October 4, 2024

BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.

Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 37 results.

Communications Medicine|October 25, 2023

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.

Nature Cancer|March 8, 2022

An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapySarah Chan, Nicole Belmar, Sun Ho, et al.

Molecular Cancer Therapeutics|March 31, 2021

Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.

ACS Medicinal Chemistry Letters|October 16, 2020

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.

Journal of Medicinal Chemistry|November 3, 2018

Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug DesignAdrian D Hobson, Russell A Judge, Ana L Aguirre, et al.

ACS Medicinal Chemistry Letters|October 15, 2014

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.

Science Advances|October 4, 2024

BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.

Pageof 4